After a period active deal-making, Wilex AG is positioning itself for some key milestones in the coming months including the reporting of an interim analysis of a Phase 3 trial of Rencarex (girentuximab), its therapy for renal cell cancer. ---Subscribe to MedNous to access this article--- Company News
